InMed Pharmaceuticals
10 hedge funds and large institutions have $138K invested in InMed Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.6% more ownership
Funds ownership: 0% → 0.6% (+0.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$40.6K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$35.7K |
| 3 |
Morgan Stanley
New York
|
+$22.7K |
| 4 |
JP Morgan Chase
New York
|
+$21.1K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$6.5K |
Top Sellers
INM Hedge Fund Activity: Q4 2020 in Review
10 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q4 2020, worth a combined $138K.
Buyers outnumbered sellers: 10 funds opened new INM positions and 0 closed out — a net gain of 10 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Bank of America, opening a new position worth an estimated $40.6K.
- 10 institutional investors held InMed Pharmaceuticals (INM) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $138K of InMed Pharmaceuticals stock for Q4 2020.
- 10 funds opened new InMed Pharmaceuticals positions in Q4 2020 and 0 closed out, a net change of +10 holders.
- The largest InMed Pharmaceuticals buyer in Q4 2020 was Bank of America, an estimated $40.6K added.
Based on aggregated 13F filings for Q4 2020.